Effect of amlodipine and lisinopril on microalbuminuria in patients with essential hypertension: A prospective study

S Jalal, F A Sofi, S M Abass, M S Alai, M A Bhat, H A Rather, N A Lone, M A Siddiqi, S Jalal, F A Sofi, S M Abass, M S Alai, M A Bhat, H A Rather, N A Lone, M A Siddiqi

Abstract

Microalbuminuria can be present in 25-100% of patients with essential hypertension and is associated with increased incidence of cardiovascular events. Our goal was to evaluate the effect of a commonly used calcium channel blocker, amlodipine, and an angiotensin converting enzyme inhibitor, lisinopril on urinary albumin excretion in patients with mild to moderate essential hypertension. We screened 324 patients with essential hypertension for microalbuminuria and documented it in 120 patients. These 120 patients with microalbuminuria were randomly divided into two groups of 60 each, matched for age, sex, arterial pressure, creatinine clearance, and urinary albumin excretion so as to receive amlodipine or lisinopril. We prospectively measured their urinary albumin excretion and creatinine clearance prior to treatment and, four and eight weeks after treatment with amlodipine or lisinopril. Mean arterial pressure (mean +/- SD) at baseline, after four weeks, and after eight weeks was 113.01 +/- 4.38,104.93 +/- 3.12, and 98.89 +/- 1.75 mmHg (P < 0.0000); and 114.13 +/- 7.11, 106.52 +/- 3.50, and 100.89 +/- 2.80 mmHg (P < 0.0000) in amlodipine and lisinopril groups, respectively. Urinary albumin excretion (mean +/- SEM) at baseline, after four, and after eight weeks was 79.30 +/- 3.74, 62.03 +/- 3.61, and 52.02 +/- 3.05 (P < 0.0000); and 73.96 +/- 4.10, 72.39 +/- 3.74, 66.12 +/- 3.94 (P = 0.1742) in lisinopril and amlodipine groups, respectively. Lisinopril but not amlodipine, reduced the urinary albumin excretion significantly despite their similar antihypertensive efficacy. The clinical and prognostic significance of these observations need to be established.

Keywords: Angiotensin converting enzyme inhibitors; calcium channel blockers; hypertension; microalbuminuria.

Conflict of interest statement

Conflict of Interest: None declared.

References

    1. Bigazzi R, Bianchi S, Campese VM, Baldari G. Prevalence of mocroalbuminuria in a large population of patients with mild to moderate essential hypertension. Nephron. 1992;61:94–7.
    1. Jalal S, Sofi FA, Alai MS, Siddiqqi MA, Bhat MA, Khan KA, et al. Prevalence of microalbuminuria in essential hypertension: A study of patients with mild to moderate hypertension. Indian J Nephrol. 2001;11:6–11.
    1. Parving HH, Mogensen CE, Evrin PE. Increased urinary albumin excretion in benign essential hypertension. Lancet. 1974;1:231–7.
    1. Losito A, Fortunati F, Zampi I, Del Favero A. Impaired functional reserve and albuminuria in essential hypertension. Br Med J. 1988;1:1562–4.
    1. Giaconi S, Levanti C, Fommei E, Innocenti F, Seghieri G, Palla L, et al. Microalbuminuria and casual and ambulatory blood pressure monitoring in normotensives and in patients with borderline and mild hypertension. Am J Hypertens. 1989;2:259–61.
    1. Bianchi S, Bigazzi R, Baldari G, Campese VM. Microalbuminuria in patients with essential hypertension: Effects of several antihypertensive drugs. Am J Med. 1992;93:525–8.
    1. Yudkin JS, Forrest RD, Jackson CA. Microalbuminuria as a predictor of vascular disease in non-diabetic subjects. Lancet. 1988;2:530–3.
    1. Marre M, Leblane H, Suarez L, Guyenne TT, Menard J, Passa P. Converting enzyme inhibition and kidney function in normotensive diabetic patients with persistent microalbuminuria. BMJ. 1987;294:1448–52.
    1. Reams GP, Bauer JH. Effect of enalapril in subjects with hypertension associated with moderate to severe renal dysfunction. Arch Intern Med. 1986;146:2145–8.
    1. Bakris GL. Effects of diltiazem or lisinopril on massive proteinuria associated with diabetes mellitus. Ann Intern Med. 1990;113:987–8.
    1. Mickish O, Schmid M, Mann JF, Helder T, Bergen F, Rauterberg EW, et al. Calcium antagonisteu bei chronischer Niereu Suffizions. Dtsch Med WO Chenschr. 1988;113:1546–8.
    1. Ferdes L, Daccordi HA, Martello M, Marisa P, Inserra F. ACE inhibitors versus calcium channel antagonists in the treatment of diabetic hypertensive patients. Hypertension. 1991;17:453.
    1. Baba T, Murabayashi S, Takebe K. Comparison of the renal effects of ACE inhibitor and calcium antagonist in hypertensive type 2 (non-insulin dependent) diabetic patients will microalbuminuria in a randomized, controlled trial. Diabetalgia. 1989;32:40–4.
    1. Stornello M, Valvo EV, Scapellato L. Hemodynamic, renal and humoral effects of the calcium entry blocker nicardipine and converting enzyme inhibitor captropril in hypertensive type II diabetic patients with nephropathy. J Cardiovasc Pharmacol. 1989;14:851–5.
    1. Bauer JH, Reems GP. Do calcium antagonists protect the human hypertensive kidney? Am J Hypertens. 1989;2:173–8.
    1. Bianchi S, Bigazzi R, Baldari G, Campese VM. Microalbuminuria in patients with essential hypertensive: Effect of an angiotensin converting enzyme inhibitor and of a calcium channel blocker. Am J Hypertens. 1991;4:291–6.
    1. Dennis VW, Robinson RR. Proteinuria. In: Seldin VW, Giebisch, editors. The kidney: Physiology and pathophysiology. New York: Raven Press; 1985.
    1. Ljungman S, Aurell M, Hartford M, Wikstrand J, Wilhelmsen L, Berglund G. Blood pressure and renal functions. Acta Med Scand. 1980;208:17–25.
    1. Mayers BD, Deen WM, Brenner BM. Effects of norepinephrine and angiotensin II on the determinants of glomerular ultrafiltration and proximal tubule fluid reabsorption in rat. Circ Res. 1975;37:101–10.
    1. Deen WM, Satvat B. Determinants of the glomerular filtration of proteins. Am J Physiol. 1981;241:I62–70.
    1. Raineri G, Andriani A, Lamontaneva G, DeCesaris R. Effects of lisinopril and amlodipine on microalbuminuria and renal functions in patients with hypertension. Clin Pharmacol Ther. 1994;56:323–30.
    1. Alli C, Lombardo M, Zanni D, Agrati AM, Cassani M, Granata S. Albuminuria and transferrinuria in essential hypertension: Effects of antihypertensive therapy. Am J Hypertens. 1996;9:1068–76.
    1. White WB, Duprez D, St Hillaire R, Krause S, Roniker B, Kuse-Hamilton J, et al. Effects of selective aldosterone blocker eplerinone versus the calcium channel antagonist, amlodipine in systolic hypertension. Hypertension. 2003;41:1021–6.
    1. De Cesaris R, Ranieri G, Filitti V, Andriani A, Bonfantino MV. Effects of atenolol and enalapril on kidney function in hypertensive diabetic patients. J Cardiovasc Pharmacol. 1993;22:208–14.
    1. Heeg IE, De Long PE, van der Hem GK, de Zeeuw D. Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. Kidney Int. 1989;36:272–9.
    1. Murelli E, Loon N, Meyer T, Peters W, Myers BD. Effects of converting enzyme inhibition on barrier function in diabetic glomerulopathy. Diabetes. 1990;39:2–8.
    1. Dzau VI. Angiotensin converting enzyme as a multimechanistic factor in CAD. J Myocard Ischemia. 1995;7:6–14.
    1. Cody RJ. The integrated effects of Angiotensin II. Am J Cardiol. 1997;79:9–11.
    1. Zanetti-Elshater F, Pingitore R, Beretta-Piecoli C, Riesen W, Heinen G. Calcium antagonists for treatment of diabetes associated hypertension: Metabolic and renal effects of amlodipine. Am J Hypertens. 1994;7:36–45.
    1. Kleinert S. HOPE for cardiovascular disease prevention with ACE inhibitor, ramipril: Heart outcomes prevention evaluation. Lancet. 1999;354:841.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit